Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA (США) 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA (США)
Список исп. литературыСкрыть список 1. Correll CU, Druss BG, Lombardo I et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010;61:892-8. 2. Druss BG, Zhao L, Von Esenwein S et al. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care 2011;49:599-604. 3. De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77. 4. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56. 5. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-16. 6. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. 7. Brunner EJ, Rees K, Ward K et al. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007;4:CD002128. 8. Ali MK, Echouffo-Tcheugui JB, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Affairs 2012; 31:67-75. 9. Daumit GL, Dickerson FB, Wang NY et al. A behavioral weightloss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594-602. 10. Bartels S, Desilets R. Health promotion programs for people with serious mental illness (prepared by the Dartmouth Health Promotion Research Team). Washington: SAMHSA-HRSA Center for Integrated Health Solutions, 2012. 11. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86. 12. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-30. 13. Jarskog LF, Hamer RM, Catellier DJ et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013;170: 1032-40. 14. Imfeld P, Bodmer M, Jick SS et al. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based casecontrol study. J Am Geriatr Soc 2012;60:916-21. 15. Vest AR, Heneghan HM, Agarwal S et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012;98: 1763-77. 16. Ahmed AT, Warton EM, Schaefer CA. The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord 2013;15:753-63.